Cargando…

Development of a Remote Mediterranean Diet Intervention for Patients With Cancer During Chemotherapy Treatment: A Mixed Methods Analysis

OBJECTIVES: The Mediterranean Diet (MedDiet) is rich in fruit, vegetables, whole grains, and bioactive compounds. Despite emerging research on the benefits of nutrition to complement the efficacy of chemotherapy and reduce symptom burden, there are few structured nutritional programs available for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleckner, Amber, Peppone, Luke, Youngblood, Shari, Reschke, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193902/
http://dx.doi.org/10.1093/cdn/nzac052.012
_version_ 1784726583321296896
author Kleckner, Amber
Peppone, Luke
Youngblood, Shari
Reschke, Jennifer
author_facet Kleckner, Amber
Peppone, Luke
Youngblood, Shari
Reschke, Jennifer
author_sort Kleckner, Amber
collection PubMed
description OBJECTIVES: The Mediterranean Diet (MedDiet) is rich in fruit, vegetables, whole grains, and bioactive compounds. Despite emerging research on the benefits of nutrition to complement the efficacy of chemotherapy and reduce symptom burden, there are few structured nutritional programs available for patients with cancer. Herein, we developed a MedDiet intervention for patients undergoing chemotherapy and identified barriers and facilitators to adherence. METHODS: This was a qualitative analysis of the intervention arm of a randomized controlled trial (NCT04534738). Participants were eligible if they had cancer (any type) and had at least 6 weeks of chemotherapy scheduled. The 8-week MedDiet intervention included home food delivery (frozen meals and MedDiet ingredients for the first 4 weeks), education, goal-setting, a cookbook, and weekly phone calls with a nutritionist. MedDiet adherence was measured using the MedDiet Adherence questionnaire at baseline, 4 weeks, and 8 weeks; change from baseline was assessed using paired t-tests at 4 and 8 weeks. After completion of the study, participants underwent a semi-structured interview to provide feedback on the program. Interviews were transcribed and themes were identified using emergent coding. RESULTS: Participants (n = 23) were 52.5 ± 13.6 years old, 91% female, and 83% White. Participants had breast (87%) or another type of cancer. MedDiet adherence score increased from 4.0 ± 2.7 at baseline to 6.7 ± 2.8 at 4 weeks and 6.5 ± 2.6 at 8 weeks (both p < 0.001). Interviews were conducted with 21 patients. While most participants (n = 15, 71%) did not actively seek nutritional information before treatment, most (n = 19, 90%) were highly engaged with the MedDiet program. Many (n = 11) volunteered feelings of empowerment and/or a welcomed a sense of control. Facilitators to adherence included accountability, structure, provision of food, palatability, and easy adoption. Barriers included chemotherapy-induced taste changes and mouth sores, others preparing food for the patient, cooking for family members’ preferences, and mental burden. CONCLUSIONS: A remote MedDiet intervention was effective and well received by patients undergoing chemotherapy. Future research should investigate how a MedDiet intervention affects clinical outcomes and symptom burden. FUNDING SOURCES: NIH National Cancer Institute.
format Online
Article
Text
id pubmed-9193902
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91939022022-06-14 Development of a Remote Mediterranean Diet Intervention for Patients With Cancer During Chemotherapy Treatment: A Mixed Methods Analysis Kleckner, Amber Peppone, Luke Youngblood, Shari Reschke, Jennifer Curr Dev Nutr Diet and Cancer OBJECTIVES: The Mediterranean Diet (MedDiet) is rich in fruit, vegetables, whole grains, and bioactive compounds. Despite emerging research on the benefits of nutrition to complement the efficacy of chemotherapy and reduce symptom burden, there are few structured nutritional programs available for patients with cancer. Herein, we developed a MedDiet intervention for patients undergoing chemotherapy and identified barriers and facilitators to adherence. METHODS: This was a qualitative analysis of the intervention arm of a randomized controlled trial (NCT04534738). Participants were eligible if they had cancer (any type) and had at least 6 weeks of chemotherapy scheduled. The 8-week MedDiet intervention included home food delivery (frozen meals and MedDiet ingredients for the first 4 weeks), education, goal-setting, a cookbook, and weekly phone calls with a nutritionist. MedDiet adherence was measured using the MedDiet Adherence questionnaire at baseline, 4 weeks, and 8 weeks; change from baseline was assessed using paired t-tests at 4 and 8 weeks. After completion of the study, participants underwent a semi-structured interview to provide feedback on the program. Interviews were transcribed and themes were identified using emergent coding. RESULTS: Participants (n = 23) were 52.5 ± 13.6 years old, 91% female, and 83% White. Participants had breast (87%) or another type of cancer. MedDiet adherence score increased from 4.0 ± 2.7 at baseline to 6.7 ± 2.8 at 4 weeks and 6.5 ± 2.6 at 8 weeks (both p < 0.001). Interviews were conducted with 21 patients. While most participants (n = 15, 71%) did not actively seek nutritional information before treatment, most (n = 19, 90%) were highly engaged with the MedDiet program. Many (n = 11) volunteered feelings of empowerment and/or a welcomed a sense of control. Facilitators to adherence included accountability, structure, provision of food, palatability, and easy adoption. Barriers included chemotherapy-induced taste changes and mouth sores, others preparing food for the patient, cooking for family members’ preferences, and mental burden. CONCLUSIONS: A remote MedDiet intervention was effective and well received by patients undergoing chemotherapy. Future research should investigate how a MedDiet intervention affects clinical outcomes and symptom burden. FUNDING SOURCES: NIH National Cancer Institute. Oxford University Press 2022-06-14 /pmc/articles/PMC9193902/ http://dx.doi.org/10.1093/cdn/nzac052.012 Text en © The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diet and Cancer
Kleckner, Amber
Peppone, Luke
Youngblood, Shari
Reschke, Jennifer
Development of a Remote Mediterranean Diet Intervention for Patients With Cancer During Chemotherapy Treatment: A Mixed Methods Analysis
title Development of a Remote Mediterranean Diet Intervention for Patients With Cancer During Chemotherapy Treatment: A Mixed Methods Analysis
title_full Development of a Remote Mediterranean Diet Intervention for Patients With Cancer During Chemotherapy Treatment: A Mixed Methods Analysis
title_fullStr Development of a Remote Mediterranean Diet Intervention for Patients With Cancer During Chemotherapy Treatment: A Mixed Methods Analysis
title_full_unstemmed Development of a Remote Mediterranean Diet Intervention for Patients With Cancer During Chemotherapy Treatment: A Mixed Methods Analysis
title_short Development of a Remote Mediterranean Diet Intervention for Patients With Cancer During Chemotherapy Treatment: A Mixed Methods Analysis
title_sort development of a remote mediterranean diet intervention for patients with cancer during chemotherapy treatment: a mixed methods analysis
topic Diet and Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193902/
http://dx.doi.org/10.1093/cdn/nzac052.012
work_keys_str_mv AT kleckneramber developmentofaremotemediterraneandietinterventionforpatientswithcancerduringchemotherapytreatmentamixedmethodsanalysis
AT pepponeluke developmentofaremotemediterraneandietinterventionforpatientswithcancerduringchemotherapytreatmentamixedmethodsanalysis
AT youngbloodshari developmentofaremotemediterraneandietinterventionforpatientswithcancerduringchemotherapytreatmentamixedmethodsanalysis
AT reschkejennifer developmentofaremotemediterraneandietinterventionforpatientswithcancerduringchemotherapytreatmentamixedmethodsanalysis